How early would we really administer biologics?;Wie früh würden wir Biologika wirklich einsetzen?

Zeitschrift fur Rheumatologie

Volumn 71, Issue 10, 2012, Pages 838-839

  Nusslein H G ^a  

^a Internistisch rheumatologische Schwerpunktpraxis ^*  (Germany)

Author keywords

Biologics; DMARD; EULAR recommendations; Rheumatoid arthritis; TNF alpha inhibitors

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOLOGICAL THERAPY; HUMAN; MEDICAL DOCUMENTATION; MONOTHERAPY; RHEUMATOLOGY; DRUG ADMINISTRATION; DRUG ANTAGONISM; GERMANY; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; STANDARD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DRUG ADMINISTRATION SCHEDULE; GERMANY; HUMANS; INTERNATIONALITY; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84877088978     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-012-1091-8     Document Type: Article

References (4)

1. UCB-Satellitensymposium .,Blick in die Zukunft: Vorhersehbarkeit des Therapieerfolges bei der RA". DGRh 2011, München
2. Smolen JS, Landewé R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
3. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631-637
4. O'Dell JR (2004) Drug therapy: therapeutic strategies for rheumatoid arthritis. New Engl J Med 350:2591-2602